-
- Rushad Patell
- Division of Hematology and
-
- Thomas Bogue
- Division of Hematology and
-
- Anita Koshy
- Division of Hematology and
-
- Poorva Bindal
- Division of Hematology and
-
- Mwanasha Merrill
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
-
- William C. Aird
- Division of Hematology and
-
- Kenneth A. Bauer
- Division of Hematology and
-
- Jeffrey I. Zwicker
- Division of Hematology and
書誌事項
- 公開日
- 2020-09-10
- DOI
-
- 10.1182/blood.2020007938
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with a high incidence of thrombotic events during hospitalization; however, data examining rates of thrombosis after discharge are limited. We conducted a retrospective observational cohort study of discharged patients with confirmed COVID-19 not receiving anticoagulation. The cohort included 163 patients with median time from discharge to last recorded follow-up of 30 days (interquartile range [IQR], 17-46 days). The median duration of index hospitalization was 6 days (IQR, 3-12 days) and 26% required intensive care. The cumulative incidence of thrombosis (including arterial and venous events) at day 30 following discharge was 2.5% (95% confidence interval [CI], 0.8-7.6); the cumulative incidence of venous thromboembolism alone at day 30 postdischarge was 0.6% (95% CI, 0.1-4.6). The 30-day cumulative incidence of major hemorrhage was 0.7% (95% CI, 0.1-5.1) and of clinically relevant nonmajor bleeds was 2.9% (95% CI, 1.0-9.1). We conclude that the rates of thrombosis and hemorrhage appear to be similar following hospital discharge for COVID-19, emphasizing the need for randomized data to inform recommendations for universal postdischarge thromboprophylaxis.</jats:p>
収録刊行物
-
- Blood
-
Blood 136 (11), 1342-1346, 2020-09-10
American Society of Hematology